Student Work

Assessing Human Immunodeficiency Virus (HIV) Protease Inhibition with Resistant Variants and Novel Inhibitors

Pubblico

Contenuto scaricabile

open in viewer

HIV Protease Inhibitors (PIs) have become one of the most effective anti-viral drugs on the market. Darunavir (DRV), the most potent FDA-approved PI, has been essential in the fight against HIV/AIDS. However, the ability of the HIV protease to mutate and grow resistance has become a global concern. To address this issue, two new series of PIs were designed using the substrate envelope hypothesis. UMass 1-10 and the mono-/di-hydroxyl series compounds are derived from the DRV backbone, with modifications made on the P1' and P2' sites. The compounds were kinetically tested against resistant mutants and crystal structures were solved. Pico-molar potencies were observed for all compounds. These results can be used to design new PIs with increased efficacy against a wide range of mutants.

  • This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
Creator
Publisher
Identifier
  • E-project-040718-205918
Advisor
Year
  • 2018
Sponsor
Date created
  • 2018-04-07
Resource type
Major
Rights statement

Relazioni

In Collection:

Articoli

Elementi

Permanent link to this page: https://digital.wpi.edu/show/6969z261n